Wednesday, May 30, 2018

Best Insurance Stocks To Own Right Now

tags:PFG,AIG,PRU,AON,

Kathy Stack knows the importance of maintaining her retirement savings in her 70s: she��s 72, battling Alzheimer��s disease and took care of her sick husband before he went to an assisted living facility before he died.

Her husband had a pension, but it wasn��t going to get them very far, she said. Her doctor told her four years ago she would have full-blown Alzheimer��s in five years, and she is working with a financial adviser to monitor her investment accounts and find long-term care insurance. Thankfully, she has enough saved where she can donate to some of her favorite charities on the side and invest in 529 plans for her grandchildren��s future education, but she sees friends who have not planned as well, and she worries for them.

Best Insurance Stocks To Own Right Now: Principal Financial Group Inc(PFG)

Advisors' Opinion:
  • [By Shane Hupp]

    These are some of the news articles that may have impacted Accern’s scoring:

    Get Principal Financial Group alerts: Principal Financial Group (PFG) Approves New $300M Buyback (streetinsider.com) Principal Financial Group (PFG) Announces Share Repurchase Plan (americanbankingnews.com) Is Principal Large Cap Growth I Institutional (PLGIX) a Strong Mutual Fund Pick Right Now? (finance.yahoo.com) Principal Financial Group is Oversold (nasdaq.com) Principal Names New Chief Human Resources Officer (finance.yahoo.com)

    Several equities analysts have recently commented on PFG shares. Morgan Stanley decreased their target price on Principal Financial Group from $79.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 5th. Wells Fargo reaffirmed a “market perform” rating and issued a $76.00 target price on shares of Principal Financial Group in a research report on Monday, January 8th. Credit Suisse Group started coverage on Principal Financial Group in a research report on Wednesday, April 25th. They issued a “neutral” rating and a $62.00 target price on the stock. Bank of America started coverage on Principal Financial Group in a research report on Monday, March 26th. They issued a “neutral” rating and a $65.00 target price on the stock. Finally, UBS started coverage on Principal Financial Group in a research report on Friday, March 2nd. They issued a “neutral” rating and a $69.00 target price on the stock. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. Principal Financial Group currently has an average rating of “Hold” and an average price target of $71.18.

  • [By Max Byerly]

    Shore Capital reissued their hold rating on shares of Provident Financial (LON:PFG) in a report issued on Thursday.

    PFG has been the subject of several other reports. Liberum Capital reissued a sell rating and set a GBX 483 ($6.48) price objective on shares of Provident Financial in a research note on Monday, February 26th. Peel Hunt reissued a hold rating and set a GBX 870 ($11.67) price objective on shares of Provident Financial in a research note on Tuesday, February 27th. JPMorgan Chase & Co. reduced their price objective on Provident Financial from GBX 1,100 ($14.76) to GBX 750 ($10.06) and set a neutral rating for the company in a research note on Thursday, May 10th. Barclays reissued an underweight rating and set a GBX 584 ($7.84) price objective on shares of Provident Financial in a research note on Wednesday, January 31st. Finally, Societe Generale lowered Provident Financial to a hold rating and set a GBX 1,050 ($14.09) price objective for the company. in a research note on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company’s stock. Provident Financial presently has a consensus rating of Hold and a consensus price target of GBX 1,190.14 ($15.97).

  • [By Logan Wallace]

    ING Groep NV boosted its stake in Principal Financial Group Inc (NYSE:PFG) by 7.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 27,524 shares of the financial services provider’s stock after purchasing an additional 1,991 shares during the period. ING Groep NV’s holdings in Principal Financial Group were worth $1,676,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Joseph Griffin]

    KBC Group NV lowered its position in shares of Principal Financial Group Inc (NYSE:PFG) by 41.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 201,808 shares of the financial services provider’s stock after selling 142,313 shares during the period. KBC Group NV’s holdings in Principal Financial Group were worth $12,292,000 as of its most recent filing with the SEC.

Best Insurance Stocks To Own Right Now: American International Group Inc.(AIG)

Advisors' Opinion:
  • [By Logan Wallace]

    Sentry Investment Management LLC lessened its holdings in American International Group (NYSE:AIG) by 8.6% during the first quarter, HoldingsChannel reports. The firm owned 64,968 shares of the insurance provider’s stock after selling 6,147 shares during the quarter. Sentry Investment Management LLC’s holdings in American International Group were worth $3,536,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    These are some of the media stories that may have effected Accern’s rankings:

    Get American International Group alerts: AIG’s loss for European business worsens in 2017 (businessinsurance.com) $1.26 EPS Expected for American International Group (AIG) This Quarter (americanbankingnews.com) UBS: Buy AIG After Earnings Estimates ‘Bottom Out’ (finance.yahoo.com) American International Group (AIG) Stock Rating Upgraded by UBS (americanbankingnews.com) American International Group (AIG) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)

    American International Group traded up $0.36, hitting $55.15, during mid-day trading on Friday, MarketBeat.com reports. The stock had a trading volume of 9,821,608 shares, compared to its average volume of 6,828,715. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.27 and a quick ratio of 0.27. American International Group has a 1-year low of $49.57 and a 1-year high of $67.30. The firm has a market cap of $49.51 billion, a P/E ratio of 22.98, a PEG ratio of 1.01 and a beta of 1.24.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on American International Group (AIG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

     

    Losers Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering. InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday. Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81. Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections. Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results. LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss. Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit. Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings. Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss. Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight. Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings. The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results. Arcadia Biosciences, Inc. (N

Best Insurance Stocks To Own Right Now: Prudential Financial Inc.(PRU)

Advisors' Opinion:
  • [By Zacks]

    Well, given the growing demand for securitized mortgage deals, Barclays plans to package and sell these Irish loans over the next two months. The group of investors that has shown interest in buying residential mortgage backed securities includes M&G Investments, the investment management division of British insurer Prudential Plc (NYSE: PRU) and Pacific Investment Management Co. ("PIMCO").

  • [By Chuck Saletta]

    Prudential Financial (NYSE:PRU) takes such pride in its rock-solid financial condition that it uses an actual rock -- the Rock of Gibraltar�-- as its corporate symbol. Prudential Financial backs up that claim with a balance sheet that has more cash, cash equivalents, and short-term investments�than total debt on it. It also claims a debt-to-equity ratio around 0.6 and a current ratio around 1.0�, which are further signs of a solid financial condition.

  • [By Joseph Griffin]

    These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

    Get Prudential Financial alerts: Prudential (PUK) Presents At 2018 Deutsche Bank Annual Global Financial Services Conference – Slideshow (seekingalpha.com) Leston Welsh joins Prudential Group Insurance as head of Disability and Absence Management (finance.yahoo.com) Contrasting Prudential Financial (PRU) & Old Mutual (ODMTY) (americanbankingnews.com) Prudential again accused with unauthorised money deduction (vir.com.vn) An Application for the Trademark ��MULLINTBG�� Has Been Filed by Prudential Insurance Company (insurancenewsnet.com)

    Prudential Financial traded down $5.05, hitting $94.97, during midday trading on Tuesday, MarketBeat Ratings reports. 2,919,216 shares of the company’s stock were exchanged, compared to its average volume of 2,144,103. The company has a current ratio of 0.12, a quick ratio of 0.12 and a debt-to-equity ratio of 0.35. The firm has a market cap of $42.01 billion, a PE ratio of 8.98, a P/E/G ratio of 0.97 and a beta of 1.52. Prudential Financial has a one year low of $94.51 and a one year high of $127.14.

  • [By Jason Hall, Chuck Saletta, and Reuben Gregg Brewer]

    But that doesn't mean you need to make risky bets to capture solid returns, either, and buying solid companies at reasonable prices can help create a margin of safety and improve your returns, while also decreasing your risk of permanent losses. Three stocks that meet these criteria are small healthcare real-estate specialist�Caretrust REIT Inc�(NASDAQ:CTRE), financial services giant�Prudential Financial Inc�(NYSE:PRU), and energy behemoth�ExxonMobil Corporation�(NYSE:XOM).�

  • [By Max Byerly]

    Flippin Bruce & Porter Inc. grew its holdings in shares of Prudential Financial (NYSE:PRU) by 2.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 61,363 shares of the financial services provider’s stock after acquiring an additional 1,391 shares during the period. Flippin Bruce & Porter Inc.’s holdings in Prudential Financial were worth $6,354,000 as of its most recent SEC filing.

Best Insurance Stocks To Own Right Now: Aon Corporation(AON)

Advisors' Opinion:
  • [By Joseph Griffin]

    AON (NYSE:AON) had its price target hoisted by Citigroup from $160.00 to $165.00 in a report issued on Tuesday morning. They currently have a buy rating on the financial services provider’s stock.

  • [By Lisa Levin] Companies Reporting Before The Bell Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion. Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion. American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion. Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion. LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion. V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion. Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion. Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million. Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion. Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion. Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million. ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million. Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million. Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million. Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion. Genesis Energy, L.P
  • [By Logan Wallace]

    Get a free copy of the Zacks research report on AON (AON)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    State of Wisconsin Investment Board decreased its holdings in shares of Aon (NYSE:AON) by 9.2% in the 1st quarter, Holdings Channel reports. The fund owned 384,127 shares of the financial services provider’s stock after selling 38,942 shares during the quarter. State of Wisconsin Investment Board’s holdings in AON were worth $53,905,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    US Bancorp DE raised its stake in shares of Aon (NYSE:AON) by 3.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,448 shares of the financial services provider’s stock after acquiring an additional 1,178 shares during the quarter. US Bancorp DE’s holdings in AON were worth $5,676,000 as of its most recent filing with the SEC.

Tuesday, May 29, 2018

Valeant Pharmaceuticals Intl Inc (VRX) Shares Bought by First Republic Investment Management Inc.

First Republic Investment Management Inc. increased its holdings in shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) by 4.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 432,093 shares of the specialty pharmaceutical company’s stock after buying an additional 16,891 shares during the quarter. First Republic Investment Management Inc. owned 0.12% of Valeant Pharmaceuticals Intl worth $6,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in Valeant Pharmaceuticals Intl by 2.2% during the 4th quarter. Bank of New York Mellon Corp now owns 359,894 shares of the specialty pharmaceutical company’s stock worth $7,479,000 after buying an additional 7,683 shares during the last quarter. Cetera Investment Advisers purchased a new position in Valeant Pharmaceuticals Intl during the 4th quarter worth $208,000. Quadrant Private Wealth Management LLC purchased a new position in Valeant Pharmaceuticals Intl during the 4th quarter worth $357,000. Kovack Advisors Inc. purchased a new position in Valeant Pharmaceuticals Intl during the 4th quarter worth $405,000. Finally, Gabelli Funds LLC grew its stake in Valeant Pharmaceuticals Intl by 24.2% during the 4th quarter. Gabelli Funds LLC now owns 113,088 shares of the specialty pharmaceutical company’s stock worth $2,350,000 after buying an additional 22,000 shares during the last quarter. Hedge funds and other institutional investors own 50.13% of the company’s stock.

Get Valeant Pharmaceuticals Intl alerts:

Shares of Valeant Pharmaceuticals Intl opened at $22.24 on Tuesday, MarketBeat.com reports. The stock has a market capitalization of $7.77 billion, a PE ratio of 5.62, a P/E/G ratio of 0.44 and a beta of -0.35. Valeant Pharmaceuticals Intl Inc has a 52-week low of $10.94 and a 52-week high of $24.43. The company has a quick ratio of 0.92, a current ratio of 1.18 and a debt-to-equity ratio of 5.59.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.29. The company had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 27.87% and a negative net margin of 10.65%. Valeant Pharmaceuticals Intl’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.79 EPS. equities research analysts expect that Valeant Pharmaceuticals Intl Inc will post 3.33 earnings per share for the current fiscal year.

Several brokerages recently weighed in on VRX. Jefferies Group boosted their target price on Valeant Pharmaceuticals Intl to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, May 9th. HC Wainwright reaffirmed a “hold” rating and set a $16.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Monday, May 7th. Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research report on Tuesday, May 8th. BTIG Research reaffirmed a “hold” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, May 9th. Finally, Piper Jaffray Companies set a $13.00 price target on Valeant Pharmaceuticals Intl and gave the stock a “sell” rating in a research report on Wednesday, May 9th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Valeant Pharmaceuticals Intl has an average rating of “Hold” and a consensus target price of $19.26.

In other news, Director Schutter Richard U. De acquired 15,000 shares of the business’s stock in a transaction on Tuesday, May 15th. The stock was bought at an average cost of $21.83 per share, for a total transaction of $327,450.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Schutter Richard U. De acquired 10,000 shares of the business’s stock in a transaction on Thursday, March 8th. The shares were purchased at an average price of $15.34 per share, with a total value of $153,400.00. Following the completion of the purchase, the director now owns 106,062 shares in the company, valued at approximately $1,626,991.08. The disclosure for this purchase can be found here. Insiders purchased a total of 7,136,629 shares of company stock valued at $110,029,937 in the last ninety days. 11.54% of the stock is currently owned by insiders.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Institutional Ownership by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Monday, May 28, 2018

Toronto Dominion Bank Grows Holdings in Crown Castle International Corp. (CCI)

Toronto Dominion Bank raised its position in shares of Crown Castle International Corp. (NYSE:CCI) by 27.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 222,954 shares of the real estate investment trust’s stock after purchasing an additional 47,953 shares during the period. Toronto Dominion Bank’s holdings in Crown Castle International were worth $24,432,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Lido Advisors LLC purchased a new position in shares of Crown Castle International in the first quarter worth about $391,000. IFP Advisors Inc increased its holdings in shares of Crown Castle International by 15.7% in the first quarter. IFP Advisors Inc now owns 13,829 shares of the real estate investment trust’s stock worth $1,516,000 after buying an additional 1,873 shares during the period. Candriam Luxembourg S.C.A. increased its holdings in shares of Crown Castle International by 3.9% in the first quarter. Candriam Luxembourg S.C.A. now owns 29,910 shares of the real estate investment trust’s stock worth $3,279,000 after buying an additional 1,113 shares during the period. Cetera Advisors LLC increased its holdings in shares of Crown Castle International by 12.5% in the first quarter. Cetera Advisors LLC now owns 12,873 shares of the real estate investment trust’s stock worth $1,408,000 after buying an additional 1,434 shares during the period. Finally, Glen Harbor Capital Management LLC increased its holdings in shares of Crown Castle International by 39.4% in the first quarter. Glen Harbor Capital Management LLC now owns 10,428 shares of the real estate investment trust’s stock worth $1,143,000 after buying an additional 2,948 shares during the period. Institutional investors and hedge funds own 94.60% of the company’s stock.

Get Crown Castle International alerts:

Crown Castle International opened at $102.74 on Friday, according to MarketBeat. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $42.25 billion, a P/E ratio of 21.18, a price-to-earnings-growth ratio of 1.25 and a beta of 0.29. Crown Castle International Corp. has a 1 year low of $93.14 and a 1 year high of $114.97.

Crown Castle International (NYSE:CCI) last posted its quarterly earnings data on Wednesday, April 18th. The real estate investment trust reported $0.21 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.19 by ($0.98). The firm had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.31 billion. Crown Castle International had a net margin of 8.87% and a return on equity of 4.06%. The business’s revenue was up 27.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.11 earnings per share. analysts anticipate that Crown Castle International Corp. will post 5.27 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 15th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $4.20 annualized dividend and a yield of 4.09%. Crown Castle International’s payout ratio is 86.60%.

CCI has been the topic of several analyst reports. Goldman Sachs Group downgraded Crown Castle International from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, March 13th. Guggenheim reiterated a “buy” rating and issued a $115.00 price objective on shares of Crown Castle International in a report on Friday, January 26th. Cowen reissued a “buy” rating and issued a $119.00 target price on shares of Crown Castle International in a research note on Friday, April 20th. Zacks Investment Research cut Crown Castle International from a “buy” rating to a “hold” rating in a research note on Wednesday, March 28th. Finally, ValuEngine raised Crown Castle International from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Nine research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $114.75.

In other news, Director Anthony J. Melone acquired 1,979 shares of the business’s stock in a transaction on Friday, April 27th. The shares were acquired at an average cost of $101.06 per share, with a total value of $199,997.74. Following the transaction, the director now owns 10,547 shares in the company, valued at approximately $1,065,879.82. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.36% of the company’s stock.

About Crown Castle International

Crown Castle owns, operates and leases more than 40,000 cell towers and approximately 60,000 route miles of fiber supporting small cells and fiber solutions across every major U.S. market. This nationwide portfolio of communications infrastructure connects cities and communities to essential data, technology and wireless service bringing information, ideas and innovations to the people and businesses that need them.

Want to see what other hedge funds are holding CCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crown Castle International Corp. (NYSE:CCI).

Institutional Ownership by Quarter for Crown Castle International (NYSE:CCI)